Weinberg M S, Azar P, Trebbin W M, Solomon R J
Kidney Int. 1985 Dec;28(6):975-81. doi: 10.1038/ki.1985.226.
The kallikrein-kininogen-kinin system has been postulated to play a role in the regulation of blood pressure and modulation of renal salt and water transport. The activity of this system has usually been determined by measurements of urinary kallikrein excretion. However, urinary kallikrein rarely correlates with simultaneously measured urinary kinins. To further evaluate the factors influencing urinary kinin excretion, we evaluated the role of urinary kininogen in this system. Urines were analyzed from normal subjects and individuals with untreated essential hypertension and end-stage renal disease. Intact urinary kininogen was significantly correlated with urinary kinins in normal subjects (r = 0.65, P = 0.003) and essential hypertensives (r = 0.52, P = 0.026). In both essential hypertension and end-stage renal disease, urinary kinins were significantly decreased (8.00 +/- 1.93, 0.90 +/- 0.18, P less than 0.05, respectively) compared to controls (23.73 +/- 5.20). In essential hypertensives, the reduction in urinary kinins was paralleled by a reduction in intact kininogen with a normal excretion of kallikrein. In end-stage renal disease, the reduction in kinins was paralleled by a reduction in kallikrein with a normal excretion of intact kininogen. This data suggests that kininogen may be an important determinant of urinary kinin excretion in various disease states.
激肽释放酶 - 激肽原 - 激肽系统被推测在血压调节以及肾脏盐和水转运的调节中发挥作用。该系统的活性通常通过测定尿激肽释放酶排泄量来确定。然而,尿激肽释放酶很少与同时测量的尿激肽相关。为了进一步评估影响尿激肽排泄的因素,我们评估了尿激肽原在该系统中的作用。分析了正常受试者、未经治疗的原发性高血压患者和终末期肾病患者的尿液。在正常受试者(r = 0.65,P = 0.003)和原发性高血压患者(r = 0.52,P = 0.026)中,完整的尿激肽原与尿激肽显著相关。在原发性高血压和终末期肾病中,与对照组(23.73±5.20)相比,尿激肽均显著降低(分别为8.00±1.93、0.90±0.18,P < 0.05)。在原发性高血压患者中,尿激肽的减少与完整激肽原的减少平行,而激肽释放酶排泄正常。在终末期肾病中,激肽的减少与激肽释放酶的减少平行,而完整激肽原排泄正常。这些数据表明,激肽原可能是各种疾病状态下尿激肽排泄的重要决定因素。